Components
Community claim
Recovery and injury repair.
Community and market provenance
Community mention, not clinical evidence
- Source: pdf01 · Page 1
- Source: pdf01 · Page 2
- Source: pdf03 · Page 2
- Source: pdf04 · Page 3
- Source: pdf05 · Page 1
- Source: pdf05 · Page 2
- Source: pdf06 · Page 4
- Source: pdf06 · Page 10
- Source: pdf07 · Page 3
- Source: pdf08 · Page 2
- Source: pdf08 · Page 3
- Source: pdf09 · Page 2
- Source: img01 · Page 1
- Source: img03 · Page 1
- Source: img04 · Page 1
- Source: img08 · Page 1
- Source: img10 · Page 1
Evidence of the exact combination
No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.
Component links are not combination evidence. A commercial name’s composition may vary.
Uncertainty and risks
A retrospective series included four BPC + thymosin β4 cases; no randomized synergy test and no verified equivalence to every TB-500 label.
Observed in supplier/community material; prevalence not quantified.
No dosing or mixing instructions are provided.
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID34324435
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E, Padgett B.
October 16, 2026
- PMID36588717
He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M.
October 16, 2026
- R01
- R03
- R06
- R07
- R08
- R09
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026